CL2010001292A1 - Compuestos derivados de 1h-benzo[d]azepina; composicion farmaceutica; utiles para el tratamiento de un trastorno seleccionado entre obesidad, hiperfagia, trastorno obsesivo compulsivo, depresion, ansiedad, abuso de sustancias, trastornos del sueño, sofocos y/o hipogonadismo (division de solicitud de patente de invencion no 375-2005). - Google Patents

Compuestos derivados de 1h-benzo[d]azepina; composicion farmaceutica; utiles para el tratamiento de un trastorno seleccionado entre obesidad, hiperfagia, trastorno obsesivo compulsivo, depresion, ansiedad, abuso de sustancias, trastornos del sueño, sofocos y/o hipogonadismo (division de solicitud de patente de invencion no 375-2005).

Info

Publication number
CL2010001292A1
CL2010001292A1 CL2010001292A CL2010001292A CL2010001292A1 CL 2010001292 A1 CL2010001292 A1 CL 2010001292A1 CL 2010001292 A CL2010001292 A CL 2010001292A CL 2010001292 A CL2010001292 A CL 2010001292A CL 2010001292 A1 CL2010001292 A1 CL 2010001292A1
Authority
CL
Chile
Prior art keywords
azepine
benzo
pharmaceutical composition
hyperphagia
hypogonadism
Prior art date
Application number
CL2010001292A
Other languages
English (en)
Inventor
Stanley Galka Christopher
Gordon Allen John
Briner Karin
Philip Cohen Michael
Lynne Hellman Serah
Angeles Martinez Maria
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34910927&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2010001292(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CL2010001292A1 publication Critical patent/CL2010001292A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

Compuestos derivados de 1h-benzo(d)azepina; y composición farmacéutica que los comprende (Divisional Solicitud 375-2005).
CL2010001292A 2004-02-25 2010-11-25 Compuestos derivados de 1h-benzo[d]azepina; composicion farmaceutica; utiles para el tratamiento de un trastorno seleccionado entre obesidad, hiperfagia, trastorno obsesivo compulsivo, depresion, ansiedad, abuso de sustancias, trastornos del sueño, sofocos y/o hipogonadismo (division de solicitud de patente de invencion no 375-2005). CL2010001292A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US54768104P 2004-02-25 2004-02-25

Publications (1)

Publication Number Publication Date
CL2010001292A1 true CL2010001292A1 (es) 2011-07-15

Family

ID=34910927

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2010001292A CL2010001292A1 (es) 2004-02-25 2010-11-25 Compuestos derivados de 1h-benzo[d]azepina; composicion farmaceutica; utiles para el tratamiento de un trastorno seleccionado entre obesidad, hiperfagia, trastorno obsesivo compulsivo, depresion, ansiedad, abuso de sustancias, trastornos del sueño, sofocos y/o hipogonadismo (division de solicitud de patente de invencion no 375-2005).

Country Status (29)

Country Link
US (2) US8022062B2 (es)
EP (2) EP1720836B1 (es)
JP (1) JP4796047B2 (es)
KR (1) KR100848411B1 (es)
CN (3) CN102329267A (es)
AR (1) AR048242A1 (es)
AU (1) AU2005217602B2 (es)
BR (1) BRPI0507986A (es)
CA (1) CA2556390C (es)
CL (1) CL2010001292A1 (es)
CR (1) CR8566A (es)
DK (1) DK1720836T3 (es)
DO (1) DOP2005000024A (es)
EA (1) EA011011B1 (es)
EC (1) ECSP066788A (es)
ES (2) ES2468741T3 (es)
IL (1) IL177267A (es)
MA (1) MA28486B1 (es)
MY (1) MY141992A (es)
NO (1) NO20064277L (es)
NZ (2) NZ549009A (es)
PE (1) PE20060010A1 (es)
PL (1) PL1720836T3 (es)
PT (1) PT1720836E (es)
SI (1) SI1720836T1 (es)
SV (1) SV2005002025A (es)
UA (1) UA85699C2 (es)
WO (1) WO2005082859A1 (es)
ZA (1) ZA200606580B (es)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1632494A1 (en) 2004-08-24 2006-03-08 Ferring B.V. Vasopressin v1a antagonists
ES2328520T3 (es) * 2005-09-01 2009-11-13 Eli Lilly And Company 2,3,4,5-tetrahidro-1h-benzo(d)azepinas 6-sustituidas como agonistas del receptor de 5-ht2c.
CA2619450C (en) * 2005-09-01 2013-10-22 Eli Lilly And Company 6-n-linked heterocycle-substituted 2,3,4,5-tetrahydro-1h-benzo[d]azepines as 5-ht2c receptor agonists
JP5237810B2 (ja) * 2005-09-01 2013-07-17 イーライ リリー アンド カンパニー ５−ＨＴ２Ｃ受容体アゴニストとしての６−置換された２，３，４，５−テトラヒドロ−１Ｈ−ベンゾ［ｄ］アゼピン
US20080269196A1 (en) 2005-09-01 2008-10-30 Karin Briner 6-Arylalkylamino-2,3,4,5-Tetrahydro-1H-Benzo[D]Azepines as 5-Ht2c Receptor Agonists
EP2727585A1 (en) 2006-05-16 2014-05-07 Takeda Pharmaceutical Company Limited In-vivo screening method
US7897595B2 (en) 2006-05-26 2011-03-01 Forest Laboratories Holdings Limited Pyridoazepine derivatives
BRPI0715160A2 (pt) 2006-08-08 2013-06-11 Sanofi Aventis imidazolidina-2,4-dionas substituÍdas por arilamimoaril-alquil-, processo para preparÁ-las, medicamentos compeendendo estes compostos, e seu uso
EP2216023A4 (en) 2007-11-15 2013-03-13 Takeda Pharmaceutical CONDENSED PYRIDINE DERIVATIVE AND ITS USE
US8822727B2 (en) 2008-03-04 2014-09-02 Arena Pharmaceuticals, Inc. Processes for the preparation of intermediates related to the 5-HT2C agonist (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
CN101712675B (zh) * 2008-10-07 2013-07-03 江苏恒谊药业有限公司 苯并含氮杂环衍生物及其在治疗神经精神疾病药物的应用
BRPI0922770A2 (pt) * 2008-12-01 2019-09-24 Procter & Gamble sistemas de perfume
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
WO2011012622A1 (en) 2009-07-30 2011-02-03 Glaxo Group Limited Benzoxazinone derivatives for the treatment of glytl mediated disorders
DK2470552T3 (en) 2009-08-26 2014-02-17 Sanofi Sa NOVEL, CRYSTALLINE, heteroaromatic FLUORGLYCOSIDHYDRATER, MEDICINES COVERING THESE COMPOUNDS AND THEIR USE
US20120258957A1 (en) 2009-11-23 2012-10-11 Matilda Jane Bingham Heterocyclic derivatives
US20110269744A1 (en) 2010-03-12 2011-11-03 Astellas Pharma Inc. Benzazepine Compound
KR20130112848A (ko) 2010-06-02 2013-10-14 아레나 파마슈티칼스, 인크. 5-ｈｔ2ｃ 수용체 아고니스트의 제조 방법
SG188361A1 (en) * 2010-09-01 2013-04-30 Arena Pharm Inc Non-hygroscopic salts of 5-ht2c agonists
US8999970B2 (en) 2010-09-01 2015-04-07 Arena Pharmaceuticals, Inc. Administration of an anti-obesity compound to individuals with renal impairment
US20130267500A1 (en) 2010-09-01 2013-10-10 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists in the treatment of disorders ameliorated by reduction of norepinephrine level
KR20130138770A (ko) 2010-09-01 2013-12-19 아레나 파마슈티칼스, 인크. 광학적으로 활성 산을 갖는 로르카세린의 염
EP3485878A1 (en) 2010-09-01 2019-05-22 Arena Pharmaceuticals, Inc. Modified-release dosage forms of 5-ht2c agonists useful for weight management
EP2611781A1 (en) * 2010-09-01 2013-07-10 Arena Pharmaceuticals, Inc. Fast-dissolve dosage forms of 5-ht2c agonists
JP5809157B2 (ja) 2010-10-08 2015-11-10 持田製薬株式会社 環状アミド誘導体
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683703B1 (de) 2011-03-08 2015-05-27 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120050A1 (de) 2011-03-08 2012-09-13 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8809325B2 (en) 2011-03-08 2014-08-19 Sanofi Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120058A1 (de) 2011-03-08 2012-09-13 Sanofi Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2716636A4 (en) 2011-04-28 2014-11-26 Mochida Pharm Co Ltd CYCLIC AMIDE DERIVATIVE
BR112013028895A2 (pt) 2011-05-10 2016-08-09 Bayer Ip Gmbh (tio)carbonilamidinas bicíclicas
CN103030604A (zh) * 2011-10-10 2013-04-10 上海医药工业研究院 4-烷基-5-甲酰基噻唑或5-甲酰基噻唑的制备方法
CN103145619A (zh) * 2012-06-15 2013-06-12 史慎德 7-氯-6-苯磺酰氨基-2,3,4,5-四氢-1H-苯并[d]氮杂*的制备
CA2886875A1 (en) 2012-10-09 2014-04-17 Arena Pharmaceuticals, Inc. Method of weight management
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
EP2801575A1 (en) 2013-05-07 2014-11-12 Bayer CropScience AG Heteroaryldihydropyridine derivatives as fungicides
WO2015066344A1 (en) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
CN103864679B (zh) * 2014-03-21 2015-11-18 河南师范大学 一种3-甲基-2-吡啶甲酸甲酯的制备方法
CN104193656B (zh) * 2014-09-09 2016-01-06 太原理工大学 一种β-二羰基砜类化合物及其制备方法
CN105622511B (zh) * 2014-11-03 2018-01-23 北京瑞都医药科技有限公司 一种减肥药物及其制备方法
CN104496891A (zh) * 2014-12-06 2015-04-08 哈尔滨工业大学 吡啶衍生物2-叔丁氧基-6-亚甲基氯吡啶的合成方法
AU2016254049A1 (en) 2015-04-30 2017-11-02 Musc Foundation For Research Development Oxindole compounds and pharmaceutical compositions thereof
NZ738682A (en) 2015-05-22 2022-01-28 Agenebio Inc Extended release pharmaceutical compositions of levetiracetam
WO2018202487A1 (en) 2017-05-04 2018-11-08 Basf Se Substituted 5-(haloalkyl)-5-hydroxy-isoxazoles for combating phytopathogenic fungi
JPWO2019131902A1 (ja) 2017-12-27 2020-12-10 武田薬品工業株式会社 腹圧性尿失禁および便失禁の治療薬
EP3917914A1 (en) 2019-02-01 2021-12-08 Fmc Corporation Diamino-substituted pyridines and pyrimidines as herbicides
US20220227763A1 (en) 2019-05-29 2022-07-21 Syngenta Crop Protection Ag Microbiocidal derivatives
AU2020368368B2 (en) 2019-10-14 2026-03-19 The Regents Of The University Of California Broad spectrum anti-cancer compounds
BR112022021228A2 (pt) * 2020-04-26 2022-12-06 Jiangsu Nhwa Pharmaceutical Co Ltd Derivado da 1,5-di-hidro-2,4-benzodiazepin-3-ona e aplicação do mesmo
AR131541A1 (es) 2023-01-07 2025-04-09 Syngenta Crop Protection Ag Compuestos de carboxamida novedosos
WO2025109114A1 (en) 2023-11-24 2025-05-30 Syngenta Crop Protection Ag Novel carboxamide compounds
WO2025149637A1 (en) 2024-01-12 2025-07-17 Syngenta Crop Protection Ag Novel carboxamide compounds
PY2501648A (es) 2024-01-12 2025-10-31 Syngenta Crop Protection Ag Nuevos compuestos de carboxamida
WO2026008750A1 (en) 2024-07-05 2026-01-08 Syngenta Crop Protection Ag Novel carboxamide compounds

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2265890A (en) * 1939-11-25 1941-12-09 Arrow Hart & Hegeman Electric Combined face plate and receptacle
US4265890A (en) * 1978-07-07 1981-05-05 Smithkline Corporation 6-Phenyl thio- and 6-cyclohexyl thio-2,3,4,5-tetrahydro-1H-3-benzazepines
ZA792785B (en) * 1978-07-07 1980-08-27 Smithkline Corp Mercapto substituted-2,3,4,5-tetrahydro-1h-3-benzazepines
US4349472A (en) 1979-04-27 1982-09-14 Schering Corporation (S)-8(1-Adamantanecarbonyloxy)-7-chloro-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine
EP0285287A3 (en) * 1987-03-23 1990-08-16 Smithkline Beecham Corporation 3-benzazepine compounds for use in treating gastrointestinal motility disorders
US4985352A (en) 1988-02-29 1991-01-15 The Trustees Of Columbia University In The City Of New York DNA encoding serotonin 1C (5HT1c) receptor, isolated 5HT1c receptor, mammalian cells expressing same and uses thereof
GB9116824D0 (en) * 1991-08-05 1991-09-18 Smithkline Beecham Corp Chemical compounds
GB9119467D0 (en) 1991-09-12 1991-10-23 Smithkline Beecham Corp Chemical compounds
AU674613B2 (en) 1993-09-28 1997-01-02 Otsuka Pharmaceutical Co., Ltd. Quinoxaline derivative as antidiabetic agent
US5698766A (en) 1995-04-05 1997-12-16 The Regents Of The University Of California Transgenic animal model for testing drugs for treating eating disorders and epilepsy
EP1183238A1 (en) 1999-05-17 2002-03-06 Eli Lilly And Company Metabotropic glutamate receptor antagonists
WO2001007416A1 (de) 1999-07-28 2001-02-01 Lonza Ag Verfahren zur herstellung von pyridazincarbonsäurederivaten
CN1149212C (zh) 1999-09-29 2004-05-12 伊莱利利公司 用作再摄入抑制剂的哌啶衍生物
GB0005789D0 (en) 2000-03-11 2000-05-03 Knoll Ag Therapeutic agents
EP1213017A3 (en) 2000-12-05 2003-11-12 Akzo Nobel N.V. Use of a 5-HT2C receptor agonist for the treatment of hot flushes
WO2002074746A1 (en) 2001-03-16 2002-09-26 Yamanouchi Pharmaceutical Co., Ltd. Benzazepine derivatives
MXPA04000358A (es) 2001-07-13 2004-05-04 Pharmacia & Up John Company Hexahidroazepino (4,5-g) indoles e indolinas como ligandos del receptor 5-ht.
AU2002346507A1 (en) 2001-11-28 2003-06-10 Pharmacia And Upjohn Company Benzazepine derivatives and their use as 5-ht ligands
US6908939B2 (en) 2001-12-21 2005-06-21 Galderma Research & Development S.N.C. Biaromatic ligand activators of PPARγ receptors
US6953787B2 (en) 2002-04-12 2005-10-11 Arena Pharmaceuticals, Inc. 5HT2C receptor modulators

Also Published As

Publication number Publication date
JP2007523951A (ja) 2007-08-23
NZ549009A (en) 2010-08-27
ECSP066788A (es) 2006-11-16
EP2479168B1 (en) 2014-04-09
PL1720836T3 (pl) 2014-09-30
AU2005217602A1 (en) 2005-09-09
SV2005002025A (es) 2005-11-04
MY141992A (en) 2010-08-16
KR100848411B1 (ko) 2008-07-28
IL177267A0 (en) 2006-12-10
UA85699C2 (en) 2009-02-25
PE20060010A1 (es) 2006-02-11
AR048242A1 (es) 2006-04-12
SI1720836T1 (sl) 2014-06-30
US8580780B2 (en) 2013-11-12
CA2556390C (en) 2012-10-02
DK1720836T3 (da) 2014-05-05
WO2005082859A1 (en) 2005-09-09
EP2479168A1 (en) 2012-07-25
KR20070001200A (ko) 2007-01-03
CN102311387A (zh) 2012-01-11
MA28486B1 (fr) 2007-03-01
EA011011B1 (ru) 2008-12-30
US20090099155A1 (en) 2009-04-16
EP1720836B1 (en) 2014-04-16
US8022062B2 (en) 2011-09-20
AU2005217602B2 (en) 2011-02-17
CN102329267A (zh) 2012-01-25
BRPI0507986A (pt) 2007-07-24
EP1720836A1 (en) 2006-11-15
PT1720836E (pt) 2014-07-16
NO20064277L (no) 2006-11-22
CA2556390A1 (en) 2005-09-09
EA200601546A1 (ru) 2007-02-27
IL177267A (en) 2011-10-31
JP4796047B2 (ja) 2011-10-19
US20120028961A1 (en) 2012-02-02
CN1934088A (zh) 2007-03-21
ZA200606580B (en) 2008-02-27
ES2468741T3 (es) 2014-06-16
NZ586553A (en) 2011-11-25
CR8566A (es) 2006-12-01
ES2466641T3 (es) 2014-06-10
DOP2005000024A (es) 2005-11-15

Similar Documents

Publication Publication Date Title
ECSP10010042A (es) Compuestos y composiciones como moduladores de la actividad de gpr119
BR122012023120B8 (pt) Composto inibidor da recaptação de serotonina
CL2008002162A1 (es) Compuestos derivados de 3-benzoisoxazol-piperidin; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento y/o prevencion de trastornos cognitivos, adiccion a drogas, depresion, ansiedad, entre otras.
CY1124111T1 (el) Παραγοντες ρυθμισης γλουταμικου στην αντιμετωπιση ψυχικων διαταραχων
CL2007002693A1 (es) Compuestos derivados de tiazol pirazolopirimidina; y composicion farmaceutica, util para el tratamiento de trastornos tales como depresion, ansiedad, obesidad e hipertension entre otras.
ATE380029T1 (de) Prodrugs von gaba-analoga, zusammensetzungen und ihre verwendungszwecke
CR8701A (es) Moduladores canabinoides de tetrahidro-indazol
CR9697A (es) Procesos para la preparacion de compuestos de 4-amino-2-(2,6-dioxopiperidina-3-il)isoindolina-1.3 dione.
UA85699C2 (en) 6-substituted 2,3,4,5-tetrahydro-1h-benzo[d]azepines as 5-ht2c receptor agonists
CR20110103A (es) Heteroarilos sustituidos
CR8831A (es) Compuestos y metodos para el tratamiento de dislipidemia
DK1928850T3 (da) Midler til forebyggelse og behandling af lidelser, der involverer modulering af RyR-receptorerne
DK1238676T3 (da) Kombination af en serotoningenoptaghæmmer og et atypisk antipsykotikum til anvendelse ved depression, obsessiv-kompulsiv lidelse og psykoser
CL2007003183A1 (es) Compuestos biciclicos puenteados; y composicion farmaceutica, util para el tratamiento de trastornos del apetito, diabetes y obesidad entre otros.
CR10062A (es) Composiciones y metodos de tratamiento para trastornos del sistema nervioso central
UY28774A1 (es) Derivados de heteroarilaminopirazol utiles para el tratamiento de la diabetes.
TW200640529A (en) Composition for treating mental health disorders
DK1626720T3 (da) 4-(2-Phenylsulfanyl-phenyl)-piperidinderivater som serotonin-genoptagelseshæmmer
NO20073369L (no) Modulatorer av muskarinreseptorer
WO2007050793A3 (en) Methods and compositions for the treatment of marfan syndrome and associated disorders
ATE438627T1 (de) 6-substituierte- 2,3,4,5-tetrahydro-1h- benzoädüazepine als 5-ht2c-rezeptoragonisten
HN2006015130A (es) Asociacion entre la ferroquina y un derivado de artemisina para el tratamiento del paludismo
CL2007002201A1 (es) Compuestos derivados de eteres heterociclicos substituidos; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la ansiedad, depresion, trastorno obsesivo compulsivo, bulimia, trastornos del panico.
ECSP088314A (es) Moduladores de cannabinoides hexahidro-cicloheptapirazol
BRPI0408320A (pt) composto, composição farmacêutica, uso de um composto, e, método para o tratamento de um distúrbio afetivo